Literature DB >> 25126399

Novel treatment approaches in hypertensive type 2 diabetic patients.

Yaniel Castro Torres1, Richard E Katholi1.   

Abstract

Type 2 diabetes mellitus (T2DM) and hypertension represent two common conditions worldwide. Their frequent association with cardiovascular diseases makes management of hypertensive patients with T2DM an important clinical priority. Carvedilol and renal denervation are two promising choices to reduce plasma glucose levels and blood pressure in hypertensive patients with T2DM to reduce future complications and improve clinical outcomes and prognosis. Pathophysiological mechanisms of both options are under investigation, but one of the most accepted is an attenuation in sympathetic nervous system activity which lowers blood pressure and improves insulin sensitivity. Choice of these therapeutic approaches should be individualized based on specific characteristics of each patient. Further investigations are needed to determine when to consider their use in clinical practice.

Entities:  

Keywords:  Ablation; Carvedilol; Diabetes mellitus; Glucose; Hypertension; Insulin resistance; Metabolic disorders; Renal denervation

Year:  2014        PMID: 25126399      PMCID: PMC4127588          DOI: 10.4239/wjd.v5.i4.536

Source DB:  PubMed          Journal:  World J Diabetes        ISSN: 1948-9358


  77 in total

1.  Current concepts of pharmacotherapy in hypertension. Carvedilol: new considerations for its use in the diabetic patient with hypertension.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-01       Impact factor: 3.738

2.  Body fat and sympathetic nerve activity in healthy subjects.

Authors:  U Scherrer; D Randin; L Tappy; P Vollenweider; E Jéquier; P Nicod
Journal:  Circulation       Date:  1994-06       Impact factor: 29.690

3.  After myocardial infarction carvedilol improves insulin resistance compared to metoprolol.

Authors:  Okcan Basat; Sema Ucak; Selcuk Seber; Erkan Oztekin; Yuksel Altuntas
Journal:  Clin Res Cardiol       Date:  2006-02-06       Impact factor: 5.460

4.  Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure.

Authors:  Takashi Kohno; Tsutomu Yoshikawa; Akihiro Yoshizawa; Iwao Nakamura; Toshihisa Anzai; Toru Satoh; Satoshi Ogawa
Journal:  Cardiovasc Drugs Ther       Date:  2005-10       Impact factor: 3.727

5.  Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.

Authors:  Marc Dorenkamp; Klaus Bonaventura; Alexander W Leber; Julia Boldt; Christian Sohns; Leif-Hendrik Boldt; Wilhelm Haverkamp; Ulrich Frei; Mattias Roser
Journal:  Eur Heart J       Date:  2012-10-22       Impact factor: 29.983

6.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.

Authors:  Henry Krum; Markus P Schlaich; Paul A Sobotka; Michael Böhm; Felix Mahfoud; Krishna Rocha-Singh; Richard Katholi; Murray D Esler
Journal:  Lancet       Date:  2013-11-07       Impact factor: 79.321

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits.

Authors:  H Brunvand; G Liu; X L Ma; T L Yue; R R Ruffolo; G Z Feuerstein
Journal:  Eur J Pharmacol       Date:  1998-09-04       Impact factor: 4.432

9.  Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol.

Authors:  J L Mehta; L M Lopez; L Chen; O E Cox
Journal:  Am J Cardiol       Date:  1994-11-01       Impact factor: 2.778

Review 10.  Use of carvedilol in hypertension: an update.

Authors:  Gastone Leonetti; Colin G Egan
Journal:  Vasc Health Risk Manag       Date:  2012-05-18
View more
  2 in total

Review 1.  Toll-like receptor 2 and type 2 diabetes.

Authors:  Zahra Sepehri; Zohre Kiani; Ali Akbar Nasiri; Farhad Kohan
Journal:  Cell Mol Biol Lett       Date:  2016-07-28       Impact factor: 5.787

Review 2.  Renal Denervation: A Potential Novel Treatment for Type 2 Diabetes Mellitus?

Authors:  Tao Pan; Jin-he Guo; Gao-jun Teng
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.